No survival benefit was seen with bevacizumab in NSCLC

Soria, Jean-Charles
October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p19
The article discusses a study on the efficiency of adding bevacizumab to cisplatin/gemcitabine on the treatment of patients with non-small cell lung cancer. Christian Manegold, professor of medicine at Heidelberg University Medical Center in Germany, noted the result of the study. The number of patients who participated in the study and the percentage of reduction in the risk for progression of the disease are also indicated.


Related Articles

  • Mutation predicted response to erlotinib in advanced NSCLC.  // Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p19 

    The article discusses a study which reported the benefit of erlotinib for treating patients with non-small cell lung cancer if they had epidermal growth factor receptor mutations. Data from the study were presented by Rafael Rosell, chief of the medical oncology service at the Catalan Institute...

  • A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. M. H. Cullen; P. Zatloukal; S. Sörenson; S. Novello; J. R. Fischer; A. A. Joy; M. Zereu; P. Peterson; C. M. Visseren-Grul; N. Iscoe // Annals of Oncology;May2008, Vol. 19 Issue 5, p939 

    Background: This phase III randomized trial compared pemetrexed 500 mg/m2 (P500) with pemetrexed 900 mg/m2 (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy. Patients and methods: Patients with locally advanced or metastatic...

  • Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC. Maione, Paolo; Rossi, Antonio; Bareschino, Maria Anna; Sacco, Paola Claudia; Schettino, Clorinda; Falanga, Marzia; Barbato, Valentina; Ambrosio, Rita; Gridelli, Cesare // Reviews on Recent Clinical Trials;Jan2011, Vol. 6 Issue 1, p44 

    Platinum-based chemotherapy, with or without the antiangiogenetic drug bevacizumab, is the standard first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib has been recently approved as...

  • Brèves de l'AERIO. Michels, J.; Besse, B.; Thibault, C. // Oncologie;Feb2013, Vol. 15 Issue 2, p125 

    No abstract available.

  • A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Besse, B.; Heist, R. S.; Papadmitrakopoulou, V. A.; Camidge, D. R.; Beck, J. T.; Schmid, P.; Mulatero, C.; Miller, N.; Dimitrijevic, S.; Urva, S.; Pylvaenaeinen, I.; Petrovic, K.; Johnson, B. E. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p505 

    Everolimus 2.5 mg/day plus granulocyte colony-stimulating factor was identified as the feasible dose given with standard-dose cisplatin–etoposide for treatment-naive extensive-stage small-cell lung cancer (SCLC). Based on the results of this study and a study of everolimus monotherapy for...

  • A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Manegold, C.; van Zandwijk, N.; Szczesna, A.; Zatloukal, P.; Au, J. S. K.; Blasinska-Morawiec, M.; Serwatowski, P.; Krzakowski, M.; Jassem, J.; Tan, E. H.; Benner, R. J.; Ingrosso, A.; Meech, S. J.; Readett, D.; Thatcher, N. // Annals of Oncology;Jan2012, Vol. 23 Issue 1, p72 

    Background: This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC).Patients and methods: Chemotherapy-naive patients with stage IIIB or IV...

  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer†. Sun, J.-M.; Ahn, Y. C.; Choi, E. K.; Ahn, M.-J.; Ahn, J. S.; Lee, S.-H.; Lee, D. H.; Pyo, H.; Song, S. Y.; Jung, S.-H.; Jo, J. S.; Jo, J.; Sohn, H. J.; Suh, C.; Lee, J. S.; Kim, S.-W.; Park, K. // Annals of Oncology;Aug2013, Vol. 24 Issue 8, p2088 

    Background We compared late thoracic radiotherapy (TRT) with early TRT in the treatment of limited-disease small-cell lung cancer (LD-SCLC). Patients and methods Patients with LD-SCLC received four cycles of etoposide plus cisplatin every 21 days. Patients were randomly assigned to receive...

  • Non-small cell lung cancer therapy: safety and efficacy in the elderly. Glotzer, Owen S.; Fabian, Thomas; Chandra, Anurag; Bakhos, Charles T. // Drug, Healthcare & Patient Safety;Apr2013, Vol. 5, p113 

    Background: Our objective was to evaluate and review the current literature on the treatment of non-small cell lung cancer (NSCLC) in the elderly. Methods: We selected recent peer-reviewed articles addressing ageing, cancer treatment in the elderly, and lung cancer treatment in the elderly. We...

  • Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues. Sandomenico, C.; Costanzo, R.; Carillio, G.; Piccirillo, M. C.; Montanino, A.; Di Maio, M.; Rocco, G.; Normanno, N.; Perrone, F.; Morabito, A. // Current Medicinal Chemistry;Mar2012, Vol. 19 Issue 7, p961 

    Bevacizumab is a monoclonal antibody directed against Vascular Endothelial Growth Factor (VEGF). Evidence about its efficacy in addition to first-line chemotherapy in non-small-cell-lung-cancer (NSCLC) has been produced by two large randomized phase III clinical trials (ECOG 4599 and AVAiL),...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics